Floatz logo

Semaglutide

Nicotine Dependence

University of Oklahomaprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Nicotine Dependence cohort.

Asset / SponsorPhaseRating
Nicotine
Brown University
Phase 4A
VARENICLINE
University of California, San Diego
Phase 4A
Naltrexone
Yale University
Phase 4BBB
Minocycline
University of Maryland, Baltimore
Phase 4BB
Cephalexin
Mayo Clinic
Phase 4BB

View all 26 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseActive
A
Indicative · Phase 4
81 / 100
View asset →
polycystic ovary syndromeActive
BBB
Indicative · Phase 4
79 / 100
View asset →
type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →